BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 22, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
  • Dendritic cells

    EACR 2025: A look into next-generation strategies in cancer

    At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.
  • Bovine adenoviral vector-based bivalent vaccine protects mice and ferrets from influenza A and B

  • New RNAi targets KRAS G12V using a cancer cell receptor

  • EACR 2025: A look into next-generation strategies in cancer

    At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.
  • Bovine adenoviral vector-based bivalent vaccine protects mice and ferrets from influenza A and B

    Researchers from Purdue University and the U.S. Centers for Disease Control and Prevention have recently developed a novel influenza vaccine candidate that uses a bovine adenoviral (BAd) vector to deliver nucleoprotein (NP) antigens from both influenza A and B viruses, along with an autophagy-inducing peptide (C5) to enhance cellular immune responses, particularly T-cell responses.
  • New RNAi targets KRAS G12V using a cancer cell receptor

    An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the University of North Carolina (UNC) at Chapel Hill, in collaboration with Enfuego Therapeutics Inc., have developed a new RNAi designed to enter cells through the epidermal growth factor receptor (EGFR), which is commonly overexpressed in tumor cells. This targeted entry pathway could minimize the side effects associated with therapies that affect KRAS.
  • MLK3 degrader PROTAC reduces oncogenic potential of TNBC cells

    Researchers from the National Cancer Institute and their collaborators have presented data regarding a MLK3-degrading PROTAC, CEP1347-VHL-02, for treating triple-negative breast cancer.
  • Chinese scientists patent new EED degradation inducers

    Researchers at Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to a polycomb protein EED-targeting moiety through linkers; they are reported to be useful for the treatment of cancer.
  • COG5 unveiled as a therapeutic target in multiple myeloma

    Multiple myeloma bone disease (MBD) lacks effective biomarkers; recent evidence involves exosomal circRNAs in the progression of cancer, but their roles in the field have not been deeply explored. The aim of this study was to explore the role of component of oligomeric golgi complex 5 (COG5) and shed light on its osteolytic mechanism.
  • Combination of activated dendritic cells and anti-TIGIT immunotherapy to eliminate latent HIV reservoirs

    Illustration of HIV particles
  • Astrazeneca divulges new ER-α degradation inducers

  • Blueprint Medicines describes new CDK2 degradation inducers

  • A stabler peptide linker in ADCs for safer, more effective cancer therapy

    Concept art of an antibody-drug conjugate
  • New PRMT5 inhibitors disclosed in Hansoh patents

  • Chia Tai Tianqing Pharmaceutical discovers new POLθ inhibitors

  • Metabolic markers to predict efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

    Xray showing lung cancer on tablet

BioWorld Insider Podcast

Play buttonRobert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.
Listen now

Conferences

  • Acute myeloid leukemia illustration

    BAL-0891 induces potent antileukemic effect in preclinical AML

    European Hematology Association

    Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia (AML) treatment. The compound was tested both in vitro and in vivo in the preclinical setting.

  • AZD-1390 + T-DXd shows synergy reducing tumor growth in TNBC

    Cancer
    About 30%-40% of triple-negative breast cancers (TNBC) show HER2-low status and may benefit from the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Ataxia-telangiectasia mutated (ATM) kinase plays a crucial role in double-strand break (DSB) repair response, thus inhibitors of...
  • Microscopic image of acute myeloid leukemia (AML) cells.

    HPK1 inhibitor BGB-15025 exerts antileukemic activity in mice

    European Hematology Association
    Despite an initial complete remission of 60%-80% in patients receiving anthracycline/cytarabine induction, acute myeloid leukemia (AML) shows a suboptimal long-term outcome rate. Serine/threonine kinase HPK1 has emerged as a promising therapeutic target, demonstrating pan-cancer prognostic...
  • Test tubes, dropper and capsules

    SAN-523 demonstrates anti-inflammatory efficacy in preclinical models of microcrystalline arthropathies

    Musculoskeletal
    University of Lausanne has reported promising preclinical data on SAN-523, a first-in-class positive allosteric modulator of cystathionine gamma-lyase (CSE), developed as a potential therapeutic for microcrystalline arthropathies, including gout and calcium pyrophosphate deposition (CPPD) disease.
More in Conferences

Today's news in brief

  • Other news to note for June 19, 2025

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • Wuhan Humanwell Pharmaceutical discovers new TEAD inhibitors

  • New TYK2 inhibitors disclosed in Sudo Biosciences patents

  • Zhejiang Jingke Pharmaceuticals describes new c-Kit inhibitors

  • Actio Biosciences divulges new KCNT1 inhibitors

  • Evopoint Biosciences patents new Aurora kinase A degradation inducers

  • Genentech discovers new GTPase KRAS mutant inhibitors

  • New GLP-1R agonists disclosed in Hengrui patent

  • Assembly Biosciences describes new azetidine compounds for HSV infections

  • Shanghai Fosun Pharmaceutical patents new PARG inhibitors

  • Novartis divulges new HTT splicing modulators

Cancer

  • Vial and syringe with DNA

    DNA vaccine against high-grade serous ovarian cancer

    Immuno-oncology
    Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be upregulated in several cohorts of patients with the malignancy.
  • Synfini and O2nix Bio partner on drugs targeting FTSJ1 for cancer metastasis

    Collaboration
  • Innovo’s INNO-220 exerts antitumoral activity against lymphoma cells

    Degradation inducer
  • miR-7974 is a predictor of poor survival in ER+ breast cancer

    Conferences
  • Medicovestor’s Adobind MC-001 awarded US orphan drug designation

    Regulatory
More in Cancer

Infection

  • Colorized transmission electron micrograph of SARS-CoV-2 (UK B.1.1.7 variant).

    Researchers develop NSP8-derived peptides successfully targeting SARS-CoV-2 replication machinery

    Coronavirus
    Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 replication complex, offering a potential new avenue for antiviral therapy.
  • European researchers divulge new ECF inhibitors

    Patents
    Scientists at Helmholtz Zentrum für Infektionsforschung GmbH, Rijksuniversiteit Groningen and Université de Lausanne have synthesized energy-coupling factor (ECF) transporter (bacterial) inhibitors reported to be useful for the treatment of enterococcal and streptococcal infections.
  • Gates Foundation grant supports Octant’s new program in HPV-related cancers

    Cancer
    Octant Inc. has received a $4.9 million grant from the Gates Foundation to support a new therapeutics program focused on human papillomavirus (HPV)-related cancers. The initiative will develop affordable, broad-spectrum, small-molecule antiviral drugs designed to disrupt the interaction between...
  • Emory University discovers viral protease inhibitors

    Patents
  • Gilead Sciences divulges new compounds to treat herpes virus infection

    Patents
  • Immunoprecise Antibodies discovers highly conserved epitope across all four dengue virus serotypes

    Immune
  • JMX-0312 protects hamsters from adenoviral lethal infection, study demonstrates

More in Infection

Neurology/psychiatric

  • University of Sydney divulges new TSPO ligands

    Patents
    University of Sydney has synthesized translocator protein (TSPO; PBR) (A147T mutant) ligands reported to be useful for the diagnosis and treatment of neurological disorders.
  • Biogen patents new HTT splicing modulators

    Patents
    Biogen Inc. has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of Huntington’s disease and spinal muscular atrophy (SMA).
  • Amyloid beta peptides on neurons

    TMEM119 clears amyloid beta deposits in AD mice

    Conferences
    Alzheimer’s disease (AD) progression involves microglial activation, and restoring or maintaining microglia homeostasis is a therapeutic approach to fight against AD.
  • Centessa’s OX2R agonist ORX-142 gains IND clearance

    Regulatory
    Centessa Pharmaceuticals plc has obtained IND clearance from the FDA to initiate a phase I study of ORX-142 in healthy volunteers. ORX-142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders.
  • Nanjing Mingde New Drug Research discovers new KCNQ2/3 activators

    Patents
    Nanjing Mingde New Drug Research Co. Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy.
More in Neurology/psychiatric

Immune

  • A human heart developed in a pig embryo over 21 days

  • AM-1476 inhibits 5-HT2B receptor with preclinical antifibrotic effects

  • New tracer has diagnostic utility for rheumatoid arthritis

  • Glucocorticoid ADC targets immune cells in disease models

  • Dana-Farber Cancer Institute patents new SHP-1 agonists

  • A carborane agonist of estrogen receptor β against systemic lupus erythematosus

  • CSPC and Astrazeneca establish strategic research collaboration

  • KT-501 depletes B cells in autoimmune diseases

  • EGL-003 selectively expands Tregs and prevents inflammation

  • Epimab sells bispecific T-cell engager to Juri in $210M deal

Endocrine/metabolic

  • Cholesterol plaque in artery

    PPRHs lower levels of PCSK9 and cholesterol in transgenic mouse without causing toxicity

    Cardiovascular
    Researchers from the Universitat de Barcelona and Oregon Health & Science University have developed a novel gene silencing technique using polypurine reverse Hoogsteen hairpins (PPRH) to target and inhibit the expression of PCSK9.
  • Biomea Fusion’s BMF-650 yields weight loss, appetite suppression in nonhuman primates

  • Ascletis Pharma discovers new GLP-1R agonists

    Patents
  • Ibio nominates IBIO-610 as obesity development candidate

    Antibody
  • MBX Biosciences files IND application for MBX-4291 for obesity

    Regulatory
More in Endocrine/metabolic

Biomarkers

  • Woman and molecular overlay

    Taurine aging biomarker story gets more complicated

    Science
    A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025, in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent,...
  • MCTP2 induces oral cancer progression and metastasis

    Cancer
    Head and neck cancer is the sixth most common cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for about 2% of all cancers and 1.9% of cancer-related deaths globally. OSCC is characterized by local invasiveness and lymph node metastatic ability, making it a very malignant cancer.
  • FFAR4 as biomarker of glomerular injury and aging

    Aging
    Researchers have discovered that reduced expression of the free fatty acid receptor 4 (FFAR4) is a biomarker of podocyte injury and aging, as well as a therapeutic target. Podocyte injury leads to progression of glomerular disease and aging, but the underlying mechanisms are poorly understood.
  • Stress sensor inhibition ameliorates Alzheimer's pathology in mice

    Neurology/psychiatric
  • Pan-cancer proteome atlas reveals new biomarkers and targets

    Cancer
  • Long noncoding RNA OIP5-AS1 inhibits lung cancer progression in preclinical studies

    Cancer
  • DNAJC7 involved in hepatocellular carcinoma progression and prognosis

    Cancer
More in Biomarkers

Gastrointestinal

  • Engineered anti-IL-23 receptor antibody enables oral delivery to treat inflammatory bowel disease

    Antibody
    Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel disease in animal models.
  • Gut microbiome leads to metabolic and immune changes after transplant

    Science
    Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
  • Korean scientists divulge new ADAMTS4 inhibitors for hepatic fibrosis

    Patents
    Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
  • New LPAM-1 antagonists disclosed in Dice Molecules patent

    Patents
    Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
  • Gut microbiome leads to metabolic and immune changes after transplant

    Science
    Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the...
  • 17β-HSD13 inhibitors described in Astrazeneca patent

    Patents
    Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • The importance of balancing AI and people in drug development
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO
  • Capricor’s CEO pursues a BLA and talks rare disease
  • The first half of 2024 was strong as M&As and financings dominate

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing